JP2009502931A - 体重減少を促すための組成物 - Google Patents

体重減少を促すための組成物 Download PDF

Info

Publication number
JP2009502931A
JP2009502931A JP2008524072A JP2008524072A JP2009502931A JP 2009502931 A JP2009502931 A JP 2009502931A JP 2008524072 A JP2008524072 A JP 2008524072A JP 2008524072 A JP2008524072 A JP 2008524072A JP 2009502931 A JP2009502931 A JP 2009502931A
Authority
JP
Japan
Prior art keywords
compound
derivatives
group
agonist
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502931A5 (cg-RX-API-DMAC7.html
Inventor
ゲイリー・トレフソン
アンソニー・エー・マッキニー
ミシェル・エス・ヒギン
ジョン・エム・マコール
Original Assignee
オレキシジェン・セラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレキシジェン・セラピューティクス・インコーポレーテッド filed Critical オレキシジェン・セラピューティクス・インコーポレーテッド
Publication of JP2009502931A publication Critical patent/JP2009502931A/ja
Publication of JP2009502931A5 publication Critical patent/JP2009502931A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008524072A 2005-07-27 2006-07-24 体重減少を促すための組成物 Pending JP2009502931A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70287705P 2005-07-27 2005-07-27
PCT/US2006/028875 WO2007016108A1 (en) 2005-07-27 2006-07-24 Compositions for affecting weight loss

Publications (2)

Publication Number Publication Date
JP2009502931A true JP2009502931A (ja) 2009-01-29
JP2009502931A5 JP2009502931A5 (cg-RX-API-DMAC7.html) 2009-09-10

Family

ID=37198787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524072A Pending JP2009502931A (ja) 2005-07-27 2006-07-24 体重減少を促すための組成物

Country Status (12)

Country Link
US (1) US20070117827A1 (cg-RX-API-DMAC7.html)
EP (1) EP1907005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009502931A (cg-RX-API-DMAC7.html)
KR (1) KR20080042092A (cg-RX-API-DMAC7.html)
CN (1) CN101237886A (cg-RX-API-DMAC7.html)
AU (1) AU2006275914A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613911A2 (cg-RX-API-DMAC7.html)
CA (1) CA2614539A1 (cg-RX-API-DMAC7.html)
IL (1) IL188442A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008001136A (cg-RX-API-DMAC7.html)
RU (1) RU2007147609A (cg-RX-API-DMAC7.html)
WO (1) WO2007016108A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
CA2702680A1 (en) 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
AU2009249071A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT3222280T (pt) 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB201704911D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254208A1 (en) * 2003-04-29 2004-12-16 Eckard Weber Compositions for affecting weight loss

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254208A1 (en) * 2003-04-29 2004-12-16 Eckard Weber Compositions for affecting weight loss

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5008010789; STROMBERG,M. F.,ET AL.: '"A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or suc' PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR VOL.72, 2002, PP.483-490 *
JPN5008010790; OLSEN,L. D.,ET AL.: '"Conjugate Addition Ligands of Opioid Antagonists. Methacrylate Esters and Ethers of 6alpha- and 6beta-Na' JOURNAL OF MEDICINAL CHEMISTRY VOL.33,NO.2, 1990, PP.737-741 *

Also Published As

Publication number Publication date
WO2007016108A1 (en) 2007-02-08
BRPI0613911A2 (pt) 2011-02-22
CN101237886A (zh) 2008-08-06
AU2006275914A1 (en) 2007-02-08
EP1907005A1 (en) 2008-04-09
US20070117827A1 (en) 2007-05-24
RU2007147609A (ru) 2009-09-10
KR20080042092A (ko) 2008-05-14
CA2614539A1 (en) 2007-02-08
MX2008001136A (es) 2008-03-13
IL188442A0 (en) 2008-04-13
WO2007016108B1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
JP4343948B2 (ja) 体重減少に影響を及ぼすための組成物
JP2008509142A (ja) 体重減少に影響を及ぼすためのブプロピオンと第2の化合物との組合せ
CN101370488B (zh) 增加胰岛素敏感性的组合物
US20100179129A1 (en) Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20090018115A1 (en) Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20070117827A1 (en) Compositions for affecting weight loss
US11666582B2 (en) Medicament for treating cough
TW200803901A (en) Methods of treating anxiety disorders
CN101472583A (zh) 改善患有肾功能受损的个体的利尿的方法
HK1157630A (en) Compositions for affecting weight loss comprising an opioid antagonist and bupropion
CN101506209A (zh) 不穿过血-脑屏障的kw-3902结合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121023